Glycopyrrolate inhalation - Chiesi

Drug Profile

Glycopyrrolate inhalation - Chiesi

Alternative Names: CHF-5259; Extrafine glycopyrronium bromide pMDI

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 23 Mar 2017 Chiesi plans a phase II trial for Chronic obstructive pulmonary disease (NCT03084796)
  • 06 Feb 2017 Chiesi completes the GlycoNEXT phase II trial in Chronic obstructive pulmonary disease (Treatment-experienced) in Czech Republic, Germany, Hungary and Romania (NCT02680197)
  • 03 Sep 2016 Efficacy data from the phase II Trigon trial in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top